An open-label, randomized, two-dose, parallel group trial of Ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with fludarabine and cyclophosphamide, in patients with previously untreated B-cell Chronic Lymphocytic Leukemia
Laufzeit: 01.01.2007 - 31.12.2014